Download Publications, 2006

Publications, 2006
Department of Oncology, Lund University Hospital, Lund
1.
Bjurberg M., Gustavsson A., Ohlsson T. and Brun E. FDG-PET in the detection of
residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a
Swedish centre. Acta Oncol 2006;45(6):743-9.
2.
Bradlow H. L., Jernstrom H., Sepkovic D. W., Klug T. L. and Narod S. A.
Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alphahydroxyestrogen metabolites. Mol Genet Metab 2006;87(2):135-46.
3.
Brans B., Linden O., Giammarile F., Tennvall J. and Punt C. Clinical applications of
newer radionuclide therapies. Eur J Cancer 2006;42(8):994-1003.
4.
Carlsson C., Bendahl P. O., Nilsson K. and Nilbert M. Benefits from membership in
cancer patient associations: Relations to gender and involvement. Acta Oncol
2006;45(5):559-63.
5.
Carlsson C., Nilbert M. and Nilsson K. Patients' involvement in improving cancer
care: experiences in three years of collaboration between members of patient
associations and health care professionals. Patient Educ Couns 2006;61(1):65-71.
6.
Chickarmane V., Troein C., Nuber U. A., Sauro H. M. and Peterson C. Transcriptional
Dynamics of the Embryonic Stem Cell Switch. PLoS Comput Biol 2006;2(9).
7.
Clendenning M., Hampel H., Lajeunesse J., Lindblom A., Lockman J., Nilbert M.,
Senter L., Sotamaa K. and de la Chapelle A. Long-range PCR facilitates the
identification of PMS2-specific mutations. Hum Mutat 2006;27(11):1155.
8.
Dahlgren N. Ryggtavlans känsel felbeskriven i dermatomkartor. Läkartidningen
2006;103(47):3702-3703.
9.
Davidsson J., Heidenblad M., Borg A. and Johansson B. Array-based comparative
genomic hybridization characterization of cytogenetically polyclonal myeloid
malignancies. Cancer Genet Cytogenet 2006;169(2):179-80.
10.
Domanski H. A., Akerman M., Engellau J., Gustafson P., Mertens F. and Rydholm A.
Fine-needle aspiration of neurilemoma (schwannoma). A clinicocytopathologic study
of 116 patients. Diagn Cytopathol 2006;34(6):403-12.
11.
Engleson J., Soller M., Panagopoulos I., Dahlen A., Dictor M. and Jerkeman M.
Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old
female with response to docetaxel and radiotherapy. BMC Cancer 2006;6:69.
12.
Fernebro J., Bladstrom A., Rydholm A., Gustafson P., Olsson H., Engellau J. and
Nilbert M. Increased risk of malignancies in a population-based study of 818 softtissue sarcoma patients. Br J Cancer 2006.
13.
Fernebro J., Francis P., Eden P., Borg A., Panagopoulos I., Mertens F., VallonChristersson J., Akerman M., Rydholm A., Bauer H. C., Mandahl N. and Nilbert M.
Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J
Cancer 2006;118(5):1165-72.
14.
Goldstein A. M., Chan M., Harland M., Gillanders E. M., Hayward N. K., Avril M. F.,
Azizi E., Bianchi-Scarra G., Bishop D. T., Bressac-de Paillerets B., Bruno W., Calista
D., Cannon Albright L. A., Demenais F., Elder D. E., Ghiorzo P., Gruis N. A.,
Hansson J., Hogg D., Holland E. A., Kanetsky P. A., Kefford R. F., Landi M. T., Lang
J., Leachman S. A., Mackie R. M., Magnusson V., Mann G. J., Niendorf K., Newton
Bishop J., Palmer J. M., Puig S., Puig-Butille J. A., de Snoo F. A., Stark M., Tsao H.,
Tucker M. A., Whitaker L. and Yakobson E. High-risk melanoma susceptibility genes
and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.
Cancer Res 2006;66(20):9818-28.
15.
Goldstein A. M., Chan M., Harland M., Hayward N. K., Demenais F., Bishop D. T.,
Azizi E., Bergman W., Bianchi-Scarra G., Bruno W., Calista D., Cannon-Albright L.
A., Chaudru V., Chompret A., Cuellar F., Elder D. E., Ghiorzo P., Gillanders E. M.,
Gruis N., Hansson J., Hogg D., Holland E. A., Kanetsky P. A., Kefford R. F., Landi
M. T., Lang J. M., Leachman S., Mackie R. M., Magnusson V., Mann G., NewtonBishop J., Palmer J. M., Puig S., Puig-Butille J. A., Stark M., Tsao H., Tucker M. A.,
Whitaker L., Yakobson E., Study Group L. M. and Genomel M. G. Features
associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone
families from three continents. J Med Genet 2006.
16.
Grafstrom G., Jonsson B. A., El Hassan A. M., Tennvall J. and Strand S. E. Rat testis
as a radiobiological in vivo model for radionuclides. Radiat Prot Dosimetry
2006;118(1):32-42.
17.
Gronwald J., Tung N., Foulkes W. D., Offit K., Gershoni R., Daly M., Kim-Sing C.,
Olsson H., Ainsworth P., Eisen A., Saal H., Friedman E., Olopade O., Osborne M.,
Weitzel J., Lynch H., Ghadirian P., Lubinski J., Sun P. and Narod S. A. Tamoxifen
and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J
Cancer 2006;118(9):2281-4.
18.
Gruvberger-Saal S. K., Cunliffe H. E., Carr K. M. and Hedenfalk I. Microarrays in
breast cancer research and clinical practice - the future lies ahead. Endocrine-Related
Cancer 2006;13:1017-1031.
19.
Gruvberger-Saal S. K. and Parsons R. Is the small heat shock protein alphaB-crystallin
an oncogene? J Clin Invest 2006;116(1):30-2.
20.
Gustavsson P., Schoumans J., Staaf J., Jonsson G., Carlsson F., Kristoffersson U.,
Borg A., Nordenskjold M. and Dahl N. Hemizygosity for chromosome 2q14.2-q22.1
spanning the GLI2 and PROC genes associated with growth hormone deficiency,
polydactyly, deep vein thrombosis and urogenital abnormalities. Clin Genet
2006;69(5):441-3.
21.
Halvarsson B., Lindblom A., Rambech E., Lagerstedt K. and Nilbert M. The added
value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal
cancer. Fam Cancer 2006.
22.
Halvarsson B., Muller W., Planck M., Benoni A. C., Mangell P., Ottosson J., Hallen
M., Isinger A. and Nilbert M. Phenotypic heterogeneity in hereditary nonpolyposis
colorectal cancer: identical germline mutations associated with variable tumor
morphology and immunohistochemical expression. J Clin Pathol 2006.
23.
Heidenblad M., Hallor K. H., Staaf J., Jonsson G., Borg A., Hoglund M., Mertens F.
and Mandahl N. Genomic profiling of bone and soft tissue tumors with supernumerary
ring chromosomes using tiling resolution bacterial artificial chromosome microarrays.
Oncogene 2006.
24.
Heikkinen K., Rapakko K., Karppinen S. M., Erkko H., Knuutila S., Lundan T.,
Mannermaa A., Borresen-Dale A. L., Borg A., Barkardottir R. B., Petrini J. and
Winqvist R. RAD50 and NBS1 are breast cancer susceptibility genes associated with
genomic instability. Carcinogenesis 2006;27(8):1593-9.
25.
Henriksson E., Baldetorp B., Borg A., Kjellen E., Akervall J., Wennerberg J. and
Wahlberg P. p53 mutation and cyclin D1 amplification correlate with cisplatin
sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta
Oncol 2006;45(3):300-5.
26.
Hietala M., Sandberg T., Borg A., Olsson H. and Jernstrom H. Testosterone levels in
relation to oral contraceptive use and the androgen receptor CAG and GGC length
polymorphisms in healthy young women. Hum Reprod 2006.
27.
Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson
H., Pietras A., Vallon-Christersson J., Borg A., Gradin K., Poellinger L. and Pahlman
S. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially
regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer
Cell 2006;10(5):413-23.
28.
Honeth G., Staflin K., Kalliomaki S., Lindvall M. and Kjellman C. Chemokinedirected migration of tumor-inhibitory neural progenitor cells towards an intracranially
growing glioma. Exp Cell Res 2006;312(8):1265-76.
29.
Isinger A., Bhat M., Borg A. and Nilbert M. CHEK2 1100delC in patients with
metachronous cancers of the breast and the colorectum. BMC Cancer 2006;6:64.
30.
Jacobsson M., Ellervik U., Belting M. and Mani K. Selective antiproliferative activity
of hydroxynaphthyl-beta-D-xylosides. J Med Chem 2006;49(6):1932-8.
31.
Jernstrom H., Sandberg T., Bageman E., Borg A. and Olsson H. Insulin-like growth
factor-1 genotype predicts breast volume after pregnancy and hormonal contraception
and is associated with circulating insulin-like growth factor-1 levels: implications for
risk of early-onset breast cancer in young women from hereditary breast cancer
families. Int J Gynecol Cancer 2006;16 Suppl 2:497.
32.
Jernstrom H., Sellberg G., Borg A. and Olsson H. Differences in IGFBP-3 regulation
between young healthy women from BRCAX families and those belonging to
BRCA1/2 families. Eur J Cancer Prev 2006;15(3):233-41.
33.
Johannsdottir H. K., Jonsson G., Johannesdottir G., Agnarsson B. A., Eerola H.,
Arason A., Heikkila P., Egilsson V., Olsson H., Johannsson O. T., Nevanlinna H.,
Borg A. and Barkardottir R. B. Chromosome 5 imbalance mapping in breast tumors
from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer
2006;119(5):1052-60.
34.
Johansson A., Johansson T., Thompson M. S., Bendsoe N., Svanberg K., Svanberg S.
and Andersson-Engels S. In vivo measurement of parameters of dosimetric importance
during interstitial photodynamic therapy of thick skin tumors. J Biomed Opt
2006;11(3):34029.
35.
Karppinen S. M., Barkardottir R. B., Backenhorn K., Sydenham T., Syrjakoski K.,
Schleutker J., Ikonen T., Pylkas K., Rapakko K., Erkko H., Johannesdottir G., Gerdes
A. M., Thomassen M., Agnarsson B. A., Grip M., Kallioniemi A., Kere J., Aaltonen
L. A., Arason A., Moller P., Kruse T. A., Borg A. and Winqvist R. Nordic
collaborative study of the BARD1 Cys557Ser allele in 3956 cancer cases: enrichment
in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other
malignancies. J Med Genet 2006.
36.
Kjellen E., Sasaki Y., Kjellstrom J., Zackrisson B. and Wennerberg J. Recombinant
erythropoietin beta enhances growth of xenografted human squamous cell carcinoma
of the head and neck after surgical trauma. Acta Otolaryngol 2006;126(5):545-7.
37.
Klug T. L., Bageman E., Ingvar C., Rose C. and Jernstrom H. Moderate coffee and
alcohol consumption improves the estrogen metabolite profile in adjuvant treated
breast cancer patients: A pilot study comparing pre- and post-operative levels. Mol
Genet Metab 2006.
38.
Kristensen I., Johnsson M., Lind J., Nilsson P. and Karlsson M. [Distance pediatric
radiotherapy. Telemedicine a good tool to be used for discussions, exchange of
experiences and competence]. Lakartidningen 2006;103(15-16):1188-90.
39.
Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P.,
Malmstrom P., Wilking N., Bergh J. and Isola J. Basoluminal carcinoma: a new
biologically and prognostically distinct entity between basal and luminal breast cancer.
Clin Cancer Res 2006;12(14 Pt 1):4185-91.
40.
Lindgren D., Liedberg F., Andersson A., Chebil G., Gudjonsson S., Borg A., Mansson
W., Fioretos T. and Hoglund M. Molecular characterization of early-stage bladder
carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene
2006;25(18):2685-96.
41.
Link K., Moell C., Osterberg K., Persson R., Orbaek P., Garwicz S., Cavallin-Stahl E.
and Erfurth E. M. Adult survivors of childhood acute lymphoblastic leukaemia with
GH deficiency have normal self-rated quality of life but impaired neuropsychological
performance 20 years after cranial irradiation. Clin Endocrinol (Oxf)
2006;65(5):617-25.
42.
Magzoub M., Sandgren S., Lundberg P., Oglecka K., Lilja J., Wittrup A., Goran
Eriksson L. E., Langel U., Belting M. and Graslund A. N-terminal peptides from
unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res
Commun 2006;348(2):379-85.
43.
Malander S., Rambech E., Kristoffersson U., Halvarsson B., Ridderheim M., Borg A.
and Nilbert M. The contribution of the hereditary nonpolyposis colorectal cancer
syndrome to the development of ovarian cancer. Gynecol Oncol 2006;101(2):238-43.
44.
Merletti F., Richiardi L., Bertoni F., Ahrens W., Buemi A., Costa-Santos C., Eriksson
M., Guenel P., Kaerlev L., Jockel K. H., Llopis-Gonzalez A., Merler E., Miranda A.,
Morales-Suarez-Varela M. M., Olsson H., Fletcher T. and Olsen J. Occupational
factors and risk of adult bone sarcomas: a multicentric case-control study in Europe.
Int J Cancer 2006;118(3):721-7.
45.
Nimeus E., Malmstrom J., Johnsson A., Marko-Varga G. and Ferno M. Proteomic
analysis identifies candidate proteins associated with distant recurrences in breast
cancer after adjuvant chemotherapy. J Pharm Biomed Anal 2006.
46.
Nimeus-Malmstrom E., Ritz C., Eden P., Johnsson A., Ohlsson M., Strand C., Ostberg
G., Ferno M. and Peterson C. Gene expression profilers and conventional clinical
markers to predict distant recurrences for premenopausal breast cancer patients after
adjuvant chemotherapy. Eur J Cancer 2006.
47.
Norrgren K., Sjolin M., Bjorkman S., Areberg J., Johnsson A., Johansson L. and
Mattsson S. Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and
radioactive Cisplatin (191Pt) in Wistar rats. Cancer Biother Radiopharm
2006;21(5):528-34.
48.
Palsson S., Stenram U., Thompson M. S., Vaitkuviene A., Poskiene V., Ziobakiene R.,
Oyama J., Deweert M. J., Gustafsson U., Bendsoe N., Andersson-Engels S., Svanberg
S. and Svanberg K. Methods for detailed histopathological investigation and
localization of biopsies from cervix uteri to improve the interpretation of
autofluorescence data. J Environ Pathol Toxicol Oncol 2006;25(1-2):321-40.
49.
Paulsson K., Heidenblad M., Morse H., Borg A., Fioretos T. and Johansson B.
Identification of cryptic aberrations and characterization of translocation breakpoints
using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia.
Leukemia 2006.
50.
Paulsson K., Heidenblad M., Strombeck B., Staaf J., Jonsson G., Borg A., Fioretos T.
and Johansson B. High-resolution genome-wide array-based comparative genome
hybridization reveals cryptic chromosome changes in AML and MDS cases with
trisomy 8 as the sole cytogenetic aberration. Leukemia 2006;20(5):840-6.
51.
Rennstam K. and Hedenfalk I. High-throughput genomic technology in research and
clinical management of breast cancer. Molecular signatures of progression from
benign epithelium to metastatic breast cancer. Breast Cancer Res 2006;8(4):213.
52.
Ringberg A., Bageman E., Rose C., Ingvar C. and Jernstrom H. Of cup and bra size:
reply to a prospective study of breast size and premenopausal breast cancer incidence.
Int J Cancer 2006;119(9):2242-3; author reply 2244.
53.
Salnikov A. V., Heldin N. E., Stuhr L. B., Wiig H., Gerber H., Reed R. K. and Rubin
K. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in
xenograft carcinoma. Int J Cancer 2006.
54.
Scheele S., Sasaki T., Arnal-Estape A., Durbeej M. and Ekblom P. Monoclonal antimouse laminin antibodies: AL-1 reacts with laminin alpha1 chain, AL-2 with laminin
beta1 chain, and AL-4 with the coiled-coil domain of laminin beta1 chain. Matrix
Biol 2006.
55.
Schoumans J., Johansson B., Corcoran M., Kuchinskaya E., Golovleva I., Grander D.,
Forestier E., Staaf J., Borg A., Gustafsson B., Blennow E. and Nordgren A.
Characterisation of dic(9;20)(p11-13;q11) in childhood B-cell precursor acute
lymphoblastic leukaemia by tiling resolution array-based comparative genomic
hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2. Br J Haematol
2006.
56.
Schoumans J., Wincent J., Barbaro M., Djureinovic T., Maguire P., Forsberg L., Staaf
J., Thuresson A. C., Borg A., Nordgren A., Malm G. and Anderlid B. M.
Comprehensive mutational analysis of a cohort of Swedish Cornelia de Lange
syndrome patients. Eur J Hum Genet 2006.
57.
Stahl O., Eberhard J., Jepson K., Spano M., Cwikiel M., Cavallin-Stahl E. and
Giwercman A. Sperm DNA integrity in testicular cancer patients. Hum Reprod 2006.
58.
Szymanowska A., Jassem E., Dziadziuszko R., Borg A., Limon J., Kobierska-Gulida
G., Rzyman W. and Jassem J. Increased risk of non-small cell lung cancer and
frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro
polymorphism. Lung Cancer 2006;52(1):9-14.
59.
Takao K., Rickhag M., Hegardt C., Oredsson S. and Persson L. Induction of apoptotic
cell death by putrescine. Int J Biochem Cell Biol 2006;38(4):621-8.
60.
Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom
P., Wilking N., Nilsson J. and Bergh J. Topoisomerase IIalpha gene amplification
predicts favorable treatment response to tailored and dose-escalated anthracyclinebased adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian
Breast Group Trial 9401. J Clin Oncol 2006;24(16):2428-36.
61.
Thompson M. S., Andersson-Engels S., Svanberg S., Johansson T., Palsson S.,
Bendsoe N., Derjabo A., Kapostins J., Stenram U., Spigulis J. and Svanberg K.
Photodynamic therapy of nodular Basal cell carcinoma with multifiber contact light
delivery. J Environ Pathol Toxicol Oncol 2006;25(1-2):411-24.
62.
Troein C., Vallon-Christersson J. and Saal L. H. An introduction to BioArray Software
Environment. Methods Enzymol 2006;411:99-119.
63.
Wagenius M., Borg A., Johansson L., Giwercman A. and Bratt O. CHEK2*1100delC
is not an important high-risk gene in families with hereditary prostate cancer in
southern Sweden. Scand J Urol Nephrol 2006;40(1):23-5.
64.
Villman K., Sjostrom J., Heikkila R., Hultborn R., Malmstrom P., Bengtsson N. O.,
Soderberg M., Saksela E. and Blomqvist C. TOP2A and HER2 gene amplification as
predictors of response to anthracycline treatment in breast cancer. Acta Oncol
2006;45(5):590-6.
Book Chapter
1.
Brown K. M., Hedenfalk I. and Trent J. cDNA Microarrays in Cancer Research. In:
DeVita V. T., Hellman S. and Rosenberg S. A., eds. Cancer: Principles and Practise of
Oncology, 7th Edition, 2006: 13-25.
2.
Carlsson C. Patientföreningarna som företrädare och röst. In: Svedberg I. L. and
Trädgård L., eds. Det civila samhället som forskningsfält. Nya avhandlingar i ett nytt
sekel. Stockholm, 2006: 38-49.
3.
Hedenfalk I. Gene Expression Profiling Can Distinguish Tumor Subclasses of Breast
Carcinomas. In: Hofmann W. K., ed. Gene Expression Profiling by Microarrays Clinical Implications, 2006: 132-161.
4.
Tennvall J., Lundell G. and Wallin G. Management of Anaplastic Thyroid Cancer. In:
Mazzaferri E. L., Harmer C., Mallick U. and Kendall-Tayler P., eds. Practical
Management of Thyroid Cancer. London: Springer-Verlag, 2006: 403-409.